• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A composition for treating a neuronal pathology of a subject, said neuronal pathology being related to hypoxia and / or hypoglycemia affecting cells of the central nervous system.
    公开号:BE1027157B1
    申请号:E20195501
    申请日:2019-08-01
    公开日:2020-10-26
    发明作者:Stéphane Silvente；Quentin Marlier；Arnaud Rives；Nicolas Caron
    申请人:Dendrogenix；
    IPC主号:
    专利说明:

    [0001] [0001] The invention relates to the field of neuronal pathologies linked to the deprivation of glucose and / or oxygen. More specifically, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt of such a compound, for its use in the treatment and / or prevention of cerebral ischemia or of a cerebrovascular accident or of a head trauma. or brain damage due to hypoglycemia related to diabetes.
    [0002] [0002] Ischemia is a decrease in blood supply to an organ, so cerebral ischemia is a decrease in blood supply to at least part of the brain. Ischemia therefore causes the interruption of both the supply of oxygen, the supply of nutrients, such as glucose, and the elimination of toxic molecules resulting from anaerobic metabolism.
    [0003] [0003] Cerebral lischemia is involved in particular in cerebral vascular accidents (AVC) commonly called “cerebral attacks”, and head trauma.
    [0004] [0004] Strokes are the third leading cause of death behind cardiovascular disease and cancer. But these are the leading causes of severe disability and the second leading cause of dementia in the Western world. The cause of stroke is a disturbance in the blood supply to the brain. Almost 85% of strokes are ischemic in nature, which means that a blood vessel is blocked by a clot, reducing blood supply to an area of the brain. The clot can form locally in a small artery or come from the heart or from a lesion in the wall of one of the large cervical arteries. This obstruction leads to cerebral ischemia and therefore prevents a sufficient supply of oxygen and metabolites, such as glucose, to meet the metabolic and energy demands of the central nervous system. The consequences are all the more important since the brain is not able to switch from aerobic to anaerobic metabolism to produce the energy it needs. So some brain cells can die.
    [0005] [0005] The consequences of strokes depend on many factors: the speed of restoration of blood circulation, the duration of the deprivation of oxygen and / or of metabolites, such as glucose, and / or the location of the accident in the brain. The clinical manifestations result, depending on the area affected, by more or less extensive paralysis, loss of speech or language, or even a coma, with disabling sequelae risks.
    [0006] [0006] A head trauma can be mild or severe, with all possible intermediaries. Its severity depends on the existence of intracerebral lesions or the existence of an extracerebral hematoma, bleeding located between the skull and the brain. Head trauma can be accompanied by contusions, damage to neurons, edema, intracerebral hemorrhages and / or ischemia.
    [0007] [0007] Cerebral ischemia is the major threat to the functional and anatomical future of the traumatized brain. This is a global, diffuse, or multicentric ischemia, which affects the cerebral cortex as an anoxia or cardiac arrest would. Ischemia affects the whole gray matter, the part of the central nervous system tissue with the highest metabolic demand for oxygen and glucose. All brain functions are thus threatened. Cellular loss can then be massive and marked by visible cerebral atrophy.
    [0008] [0008] Lischemia can take another more local form. The microcirculation of the tissues located around a focus of contusion or hemorrhage is threatened by vasoconstriction, the effect of tissue compression, capillary micro-thrombosis, or even disorders of cell metabolism. The cell's energy production is compromised because its oxidative metabolism is broken down. Toxic products like free radicals are released. The slightest respiratory or circulatory event can then precipitate cells below the viability threshold.
    [0009] [0009] The consequences of cranial trauma can be physical damage such as paraplegia, hemiplegia, vision problems, etc. They can also be neuropsychological damage affecting memory, attention and the ability to communicate. Finally, they modify the behavior and the personality of the injured person and his daily life, as well as that of his relatives.
    [0010] [0010] Certain cases of diabetes present with hypoglycemia coupled with hypoxia, the consequences of which are deleterious for the patients affected.
    [0011] [0011] Hypoglycemia is the most common clinical complication in the daily management of diabetics treated with insulin, and continues to be the limiting factor in the glycemic management of diabetes. Severe hypoglycemia affects 40% of diabetics treated with insulin and can lead to brain damage, particularly to vulnerable neurons in the cortex and hippocampus. For example, learning and memory deficits are a direct consequence of this neuronal damage to the hippocampus caused by severe hypoglycemia.
    [0012] [0012] In addition, the combination of diabetes and hyperglycemia worsens neuronal damage resulting from other forms of central nervous system damage, such as stroke.
    [0013] It is therefore necessary to be able to at least partially treat the consequences of oxygen and / or glucose deprivation, as during cerebral ischemia, following hypoglycemia or even following hypoxia, on patients to improve their recovery.
    [0014] [0014] An idea underlying the invention is to provide preventive and / or curative treatments for neurological diseases affecting in particular neurons of the central nervous system involving hypoxia and / or hypoglycemia.
    [0015] For this, the invention provides a composition for its use in the treatment of a neuronal pathology of a subject, said neuronal pathology being linked to hypoxia and / or to hypoglycemia affecting cells of the central nervous system, said composition comprising at least one compound of formula (|): R, T, At Z,
    [0016] The COOC (CH :) 3 substituent is also called Boc.
    [0017] The compound of formula (I) belongs to the group of steroids. The numbering of the carbon atoms of the compound of formula (I) therefore follows the nomenclature defined by PIUPAC in Pure & Appl. Chem., Vol. 61, No. 10, pp. 1783-1822,1989. The numbering of the carbon atoms of a compound belonging to the steroid group according to IUPAC is illustrated below: 24 "24) 2 20.22 26 a" 8 25 24 Tag n (= 7 27; 5>) ie 2 84 is
    [0018] The methods for preparing the compound of formula (I) have already been described previously, and in particular in DE MEDINA, P. et al. Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases. Journal of Medicinal Chemistry, 52 (23), 2009, pp. 7765-7777.
    [0019] [0019] In addition, the composition can have one or more of the following characteristics, considered in isolation or in combination.
    [0020] [0020] According to one embodiment, the compound of formula (I) is defined by Z2 = 0; Rı = R4 = H; R2 = OH; Rs = H; and T4 = T2 = T3 = T4 = H. [0021] According to one embodiment, the compound of formula (I) is defined by Z: = O and Rs = H.
    [0022] [0022] According to one embodiment, the compound of formula (l) is defined by Re = - (CH2) aNH (CH2) 3NHR7 with R7 = COCH :.
    [0023] [0023] According to one embodiment, the compound of formula (I) is defined by Re = - (CH2) 2-imidazol-4-yl.
    [0024] [0024] According to one embodiment, the compound of formula (l) is defined by Re = - (CH2) sNH (CH2) 4aNHR7, - (CH2) 4ANH (CH2) sNHRz7, - (CH2) 3NH (CH2) 4NH (CH2): NHR7; or - (CH2) 4NHR7 setR7 = H.
    [0025] [0025] According to one embodiment, the compound of formula (I) is defined by Zi = 1 and Rs = H.
    [0026] [0026] According to one embodiment, the compound of formula (|) is defined by Re = - (CH2): NH (CH2) 4NHR7; - (CH2) 4NH (CH2) sNHRz7; or - (CH2): NH (CHz) 4NH (CHz): NHRz7 ‚and R7 = H.
    [0027] According to one embodiment, the at least one compound of formula (|) is defined by Z "= Z2 = 0; R, = R4 = zH; R2 = OH; Rs5 = H; Rs = (CHz) sNH (CHz2) 4NHaz; T4 = T2 = T3 = T4 = H. In this embodiment the compound is called DX243. The results obtained with this compound are particularly interesting. Indeed, a curative effect of this compound is observed against the pathophysiological phenomenon of hypoxia and / or hypoglycemia even at very low concentrations.
    [0028] According to one embodiment, the at least one compound of formula (|) is defined by Z + = Z2 = 0; Rı = R4 = H; R2 = OH; Rs = H; Re = (CH2) 4NH (CH2) sNH2; T4 = T2 = T3 = T4 = H. In this embodiment the compound is called DX245. The results obtained with this compound are particularly interesting. Indeed, we observe a curative effect of this compound against the pathophysiological phenomenon of hypoxia and / or hypoglycemia greater than that of DX243.
    [0029] According to one embodiment, the at least one compound of formula (I) is defined by Z4 = 1; Z2 = 0; R: = R4, = H; R2 = OH; Rs = H; Re = (CH2) 3NH (CH2) 4NHz; T4 = T2 = T3 = T4 = H. In this embodiment the compound is called DX242. The results obtained with this compound are particularly interesting. Indeed, a curative effect of this compound is observed against the pathophysiological phenomenon of hypoxia and / or hypoglycemia greater than that of DX243.
    [0030] According to one embodiment, the at least one compound of formula (|) is defined by Z + = 1: Z2 = 0; R; = R, = H; R: = OH; Rs = H; Re = (CH2) 4NH (CH2) 3NH2; T4 = T, = T5 = T4 = H. In this embodiment the compound is called DX244. The results obtained with this compound are particularly interesting. Indeed, we observe a curative effect of this compound against the pathophysiological phenomenon of hypoxia and / or hypoglycemia greater than that of DX243.
    [0031] [0031] According to one embodiment, the neuronal pathology of the central nervous system is taken from the group consisting of cerebral trauma and cerebrovascular accidents.
    [0032] [0032] According to one embodiment, the neuronal pathology of the central nervous system is a brain injury due to ischemia.
    [0033] [0033] According to one embodiment, the hypoglycemia is due to diabetes.
    [0034] According to one embodiment, the invention also provides a composition according to one of the preceding embodiments, in the form of a pharmaceutically acceptable aqueous solution and having a concentration of compound of formula (I) of between 10 nmol.L "* and 1 mmol.L *, preferably between 10 nmol.L” and 1 yumol.L *, more preferably between 10 nmol.L and 100 nmol.L ”.
    [0035] The invention will be better understood, and other aims, details, characteristics and advantages thereof will emerge more clearly during the following description of several particular embodiments of the invention, given solely by way of illustration. and not limiting, with reference to the accompanying drawings.
    [0036] [0036] [fig.1] Figure 1 schematically represents a protocol for studying the efficacy of compounds of formula (I), in particular DX243, on an in vitro model of ischemia.
    [0037] [0037] [fig.2] Figure 2 illustrates the results of a first test to assess neuronal survival following ischemia followed by reperfusion in the presence of DX243.
    [0038] [0038] [fig.3] Figure 3 illustrates the results of a second test to assess neuronal survival after undergoing ischemia followed by reperfusion in the presence of DX243.
    [0039] [0039] [Fig.4] Figure 4 illustrates the results of a third test to assess neuronal survival after undergoing ischemia followed by reperfusion in the presence of DX243.
    [0040] [0040] [Fig.5] Figure 5 illustrates the results of the third test to assess neuronal survival after undergoing ischemia followed by reperfusion in the presence of compounds of formula (I) other than DX243 of Table 1.
    [0041] An experimental protocol will be described below which demonstrates the protective effect of the compounds of formula (l) indicated in Table 1, including the compound DX243, against hypoxia and hypoglycemia.
    [0042] The concentrations or molarities of the compounds are expressed in moles per liter, the symbol of which is mol.L or M.
    [0043] Referring to Figure 1, the first step of the protocol for studying the neuroprotective effect of the compounds of formula (I), in particular those indicated in Table 1, consists in obtaining a primary culture of cortical neurons to from cells taken from the brains of wild-type mouse embryos put under suitable culture conditions. More specifically, the cells collected are grown in NeurobasalTM Medium (Ref. 21103049 ThermoFisher Scientific) to which L-Glutamine and B27 supplement 50X (Ref. 17504044 ThermoFisher Scientific) have been added. Neurons from the primary culture are then isolated and purified. It should be noted that it is the culture conditions themselves that make it possible to obtain a culture purified in neurons from the dissociation of the embryonic cortices. Deprivation of oxygen and glucose (DOG) is then carried out on these neurons in order to mimic as faithfully as possible what happens in vivo during a stroke, that is to say a decrease in blood pressure. supply of oxygen and glucose due to decreased blood perfusion to cells. To achieve this ischemia-mimicking oxygen and glucose deprivation, the neurons are placed for 4 hours in an incubator whose atmosphere has an oxygen content of about 1% and replacing the culture medium with a medium without glucose. As the ischemia model is a so-called ischemia / reperfusion model, the neurons are then placed in a medium containing glucose under normoxic conditions for 24 hours (reperfusion) following the ischemia step. Group A of neurons is a group of neurons which have been treated with a solution of compound of formula (I) during DOG and reperfusion, i.e. a molecule from Table 1 is added to the medium without glucose as soon as glucose and oxygen deprivation begins. The concentration of the compound of formula (I) named DX243 is between 10 nmol.L ”and 1 umol.L” in the medium without glucose. The concentration of the other molecules in Table 1 is 100 nmol.L * in the medium Without Glucose Group B of neurons is a group of neurons that have been treated with DX243 solution during reperfusion only, to approximate what is happening clinically, namely treatment possible only after several hours with conventional treatment. The DX243 solution is added to the medium without glucose as soon as reperfusion begins The concentration of DX243 is between 10 nmol.L and 1 umol.L in the medium without glucose.
    [0044] The negative control consists of a group of neurons undergoing DOG followed by reperfusion without DX243 present. This group of neurons is called “Ctrl” in FIGS. 2 to 4. The normal control consists of a group of neurons obtained from the primary culture placed under normoxic conditions for 28 h. The normal control is called “normox” in Figures 2 to 4. The positive control consists of a group of neurons from the primary culture that has undergone DOG for 4 hours in the presence of roscovitine, a cell cycle inhibitor causing cell death, followed by reperfusion for 24 hours. The positive control is referred to as "ROSCO" in Figures 2-4.
    [0045] [0045] At the end of the reperfusion, the survival of the neurons is evaluated using three different tests. The results are then compared to the results of the three survival tests of the control groups.
    [0046] In Figures 2 to 4, the stars indicate the statistical power of the results. A star indicates that it is 95% certain that the results are not due to chance. The presence of 2 stars means that he is 99% certain that the results are not due to chance, and the presence of 3 stars indicates that he is 99.9% certain that the results are not due to chance.
    [0047] [0047] Figure 2 shows the results of the first neuronal survival test in the case of the use of DX243. Graphs A and C are a representation of the results obtained for group A, and graphs B and D are a representation of the results obtained for group B. This first test is an immunocytochemical test which makes it possible to demonstrate living cells and dead cells.
    [0048] A first series of images is produced with chemical labeling by fluorescence. This labeling is carried out with DAPI (4 ', 6-diamidino-2-phenylindole) which is capable of binding strongly to the adenine (A) and thymine (T) bases of DNA. It can detect living cells. A second set of images are taken with fluorescence labeling using the CC3 antibody. The CC3 antibody can detect caspase 3, and therefore cells in a state of apoptosis.
    [0049] To visualize the proportion of healthy neurons among the different culture conditions, the TUJ1 antibody is used. TUJ1 reacts with beta-tubulin III, a structural protein that makes up tubulin and specific to neurons. Beta-tubulin III is widely used as a marker to distinguish neurons from other cell types.
    [0050] From these images, the proportion of living cells (cell survival) was calculated by determining the ratio of the number of living cells to the total number of cells. The proportion of cells in apoptosis was determined using the ratio of the number of cells detected by the CC3 antibody to the total number of cells. The values obtained were compared to those obtained by the normox group.
    [0051] It is observed that the DOG induces a decrease in the proportion of living cells on the Ctrl group on graphs A and B of FIG. 2, and an increase in the proportion of cells in apoptosis on the Ctrl group on graphs C and D of Figure 2. In contrast, both treatment with DX243 during DOG and reperfusion and treatment with DX243 only during reperfusion partially protects against neuronal death. In fact, there is an increase in the proportion of living cells and a decrease in the proportion of cells in apoptosis following treatment with DX243 in comparison with the Ctrl group. A DX243 concentration between 10 nmol.L "and 100 nmol.L * seems to correspond to an ideal concentration range to maximize the neuroprotective effects.
    [0052] [0052] In addition, it seems that post-OGD treatment for 24 hours with DX243 protects neurons even more effectively.
    [0053] [0053] To confirm the results obtained with the DX243, a test based on the metabolic activity of neurons was carried out to assess neuronal survival in another way. This test is based on the use of the tetrazolium salt MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide). Tetrazolium is reduced by mitochondrial succinate dehydrogenase of active living cells to formazan, precipitated in purple color. The amount of precipitate formed is proportional to the amount of living cells but also to the metabolic activity of each cell. Thus, a simple determination of the optical density at 550 nm by spectroscopy makes it possible to know the relative quantity of living and metabolically active cells. Since the greater the number of living cells, the greater the colorimetric intensity, the colorimetric intensity was therefore quantified and related to the intensity observed under normoxic conditions. The results obtained have been reported in graph A of figure 3 for group A and in graph B of figure 3 for group B.
    [0054] In graphs A and B of FIG. 3, it is observed that DOG causes a marked decrease in metabolically active cells in the Ctrl group. In contrast, treatment of neurons with DX243 partially protects against this decrease in survival following DOG. This effect is all the more marked for the group of neurons having benefited from DX243 than during the 24-hour reperfusion as shown in graph B of FIG. 3. On the two graphs, a treatment comprising a concentration of DX243 of between 10 nmol .L ”and 100 nmol.L”! Seems the most effective.
    [0055] [0055] A third cell survival test in the case of the use of DX243, based on the integrity of cell membranes, which is ruptured in dead cells, was performed. This last test uses trypan blue which will stain dead cells blue. The calculation of the percentage of living cells was therefore carried out by counting the proportion of blue and non-blue cells, and related to the percentage of living cells observed in the normox group. The results obtained have been reported in graph A of figure 4 for group A and in graph B of figure 4 for group B.
    [0056] It is observed that the DOG induces a significant decrease in the number of cells which have retained the integrity of their membrane, whether in graph A of FIG. 4 or on graph B of FIG. 4. The treatment of neurons with of DX243 restores the percentage of living cells to levels close to that observed in the normox group, mainly with concentrations between 10 nmol.L and 100 nmol.L ”.
    [0057] DX243 is therefore effective at concentrations between 10 nmol.L and 1 umol.L. For DX243 concentrations between 10 nmol.L * and 100 nmol.L *, the results are more stable and the protective effect of DX243 is statistically greater. This can be explained by the fragility of primary crops outside their natural environment.
    [0058] [0058] For the molecules of the table | other than the DX243 used on group A, only the third cell survival test was performed. The results obtained have been reported on the graph of FIG. 5 including therein the results obtained with the DX243. The acronym NT stands for untreated. The non-hatched NT bar corresponds to a group of neurons from the primary culture placed under normoxic conditions for 28 h. The hatched bars represent groups of neurons from the primary culture that have undergone DOG and reperfusion either without molecules from Table 1 (hatched bar called NT) or in the presence of a molecule from Table 1.
    [0059] For all the compounds tested with the exception of DX243BOC, the survival rate of the groups of neurons is higher than that of the groups of NT neurons having undergone DOG and reperfusion (hatched NT bar), they therefore exhibit an effect. neuroprotective. In particular, it should be noted that the DX245, DX244 and DX242 have a higher survival rate than that of DX243.
    [0060] The compound of formula (I) and defined by: Z1 = Z2 = 0; R1 = R4 = H; R2 = OH; R5s = H; Re = - (CH2) 3-N (COOC (CH3) 3- (CH2) 4-NH (COOC (CHa3) 3; T1 = T2 = Ta = T4 = H is called DX243BOC, shown in Table 1.
    [0061] The survival rate of the group treated with DX243BOC is for its part lower than that of the group treated with DX243 and that of the NT group having undergone DOG and reperfusion, thus demonstrating the importance of the R3 group in the activity of the compound of formula (I).
    [0062] It is therefore expected that in a pharmaceutically acceptable aqueous solution comprising the compound of formula (I), a concentration of compound of formula (I) of between 10 nmol.L ”and 1 mmol.L *, preferably between 10 nmol. .L ”and 1 µmol.L 'is more preferably between 10 nmol.L and 100 nmol.L” is effective.
    [0063] [0063] All of these results indicate that the compounds in Table 1 have a neuroprotective effect against cerebral ischemia, and therefore against cerebral trauma and cerebrovascular accidents.
    [0064] Although the experiments were carried out with ten different compounds of formula (I), it is obvious that similar results are expected for the compounds of formula (I) other than those of Table 1.
    [0065] [0065] In addition, in the context of hypoxia alone or hypoglycemia alone, an apoptotic neuronal death component is observed as in KATO, et al. Recurrent short-term hypoglycemia and hyperglycemia induce apoptosis and oxidative stress via the ER stress response in immortalized adult mouse Schwann (INMS32) cells. Neuroscience Research, November 13, 2018, retrieved from <https://www.sciencedirect.com/science/article/pii/S0168010218304371 via%3Dihub> <doi: https://doi.org/10.1016/j.neures.2018.11 .004>, in Sendoel, A., et al. Apoptotic Cell Death Under Hypoxia. Physiology, 29, pp. 168-176, 2014, or in Xu, Y., et al. Protective effect of lithium chloride agains hypoglycemia-induced apoptosis in neuronal PC12 cell. Neuroscience, 330, 25 August 2016, pp. 100-108. However, the results observed above in the ischemia / reperfusion model show a protection due to the compounds of formula (I) against this apoptotic component. In addition, hypoglycemia is able to induce oxidative stress in neuronal cells, oxidative stress present as part of oxygen and glucose deprivation and which is a major component of the induction of neuronal death. Accordingly, common mechanisms inducing neuronal death exist in neuronal death induced by hypoglycemia and hypoxia, by hypoglycemia alone and by hypoxia alone, such as apoptosis. In conclusion, the neuroprotective effect of the compounds of formulas (|) extends to cases of hypoxia alone or hypoglycemia alone.
    [0066] The use of the verb "to include", "to understand" or "to include" and its conjugated forms does not exclude the presence of other elements or other steps than those stated in a claim.
    [0067] [0067] In the claims, any reference sign in parentheses cannot be interpreted as a limitation of the claim.
    [0068] Table 1:: Ï Me: Hs: Ï e = i Me, 1! by Nen Ne | ST N 7 ve | In Ÿ y VON Ae | Dx {27 DX249 2. L ì LS | ee; ii: | | © == DX243 ot DX301 A == | ed ee PRE DR] ee i Ï MTS TS a; BET ST Sg Se ST Se Se 13 i | + i H I 3 | | Me mn i Me _; ; | | EE N or H u | | | Bj gg TS i Sf Sa D SEE | | i Ï Me i Me I i | Me! 2 Mi i Me:: ad PO: DX245 def DX4914 i Feb me u i | 39 dl A AN a i 9 dnf A. La. NH L 1 | i ve | YT ==} = ì Me Han | 3 | | 7 Ne ig; SA Twe i | I es; i Mel 10 ° mad i | PLL ME: nn rd == | DX244 eN S ets DX243B0C | PORT ii | | nj te Nt | NM SDS Do E
    权利要求:
    Claims (12)
    [1]
    1. Composition for use in the treatment of a neuronal pathology of a subject linked to hypoxia and / or hypoglycemia affecting cells of the central nervous system, said composition comprising at least one compound of formula (|): R, T, x ZZ, Ts: >>, R, O 3 R, 4 () formula in which, R4 = H, CoHan + or R-CO with R = H or CnHan-1, with n <16; R2 = H or OH; R3 = -NR5Re, Rs being H or - (CHz) sNHz, and Rs being taken from the group consisting of - (CH2) zNH (CH2) 4NHR7; - (CH2) 4NH (CHz) sNHR7; - (CHz) sNH (CHz) 4aNH (CH2) sNHR7; - (CH2): NHR7; - (CH2) 4NHR7 with R7 = H or COCHs; and - (CH2) z-imidazol-4-yl ;—( CH2)> - indol-3-yl; R4 = H or OH at position 20, 22, 24, 25, 26 or 27, positioned so as to create an asymmetric center of R or S configuration; Z and Z2 each represent the number of double bonds between carbon atoms C7 and C8 and C22 and C23 respectively (either O or 1); T1, Ta. and T3; = H or CH; independently of each other; T4 = H, CHz, C: Hs positioned so as to obtain an asymmetric center of R or S configuration in position 24; and / or at least one pharmaceutically acceptable salt of at least one compound of formula (D).
    [2]
    2. Composition according to claim 1, in which the compound of formula (I) is defined by Z2 = 0; Rı = R, = H; Ra = OH; Rs = H; andT = T2 = 1;, = 1, = H.
    [3]
    3. Composition according to claim 2, in which the compound of formula (|) is defined by Z: = 0.
    [4]
    4. Composition according to claim 3, in which the compound of formula (I) is defined by Re = - (CH2) 4aNH (CH2) 3: NHR7 with R7 = COCHz.
    [5]
    5. Composition according to Claim 3, in which the compound of formula (|) is defined by Re = - (CHz)> - imidazol-4-yl.
    [6]
    6. The composition of claim 3, wherein the compound of formula (I) is defined by Rs = - (CHz2) 3NH (CH2) 4NHR; z, - (CH2) 4NH (CH2): NHRz7, - (CHz2) sNH (CH2) 4NH (CHz) sNHRz7; OÙ - (CH2) 4NHRz7; andR7 = H.
    [7]
    7. Composition according to claim 2, in which the compound of formula (|) is defined by Z: = 1.
    [8]
    8. Composition according to Claim 7, in which the compound of formula (|) is defined by Rs = - (CH2): NH (CH2) 4NHRz7; - (CH2) 4NH (CHz): NHRz7 ‚or - (CH2) 3NH (CH2) 4NH (CH2): NHRz7; and R7 = H.
    [9]
    9. Composition according to one of claims 1 to 8, wherein the neuronal pathology of the central nervous system is taken from the group consisting of cerebral trauma and cerebrovascular accidents.
    [10]
    10. Composition according to one of claims 1 to 8, in which the neuronal pathology of the central nervous system is brain damage due to ischemia.
    [11]
    11. Composition according to one of claims 1 to 8, wherein the hypoglycemia is due to diabetes.
    [12]
    12. Composition according to one of claims 1 to 8, in the form of a pharmaceutically acceptable aqueous solution and having a concentration of compound of formula (I) of between 10 nmol.L "and 1 mmol.L *, preferably between nmol.L and 1 umol.L *, more preferably between 10 nmol.L and 100 nmol.L ”.
    类似技术:
    公开号 | 公开日 | 专利标题
    Fanjul-Moles et al.2016|Relationship between oxidative stress, circadian rhythms, and AMD
    JP4896017B2|2012-03-14|Composition for improving brain disease or brain function
    Olanow2004|The scientific basis for the current treatment of Parkinson's disease
    Rodrigo et al.2005|The role of free radicals in cerebral hypoxia and ischemia
    Kelly et al.2001|Photothrombotic brain infarction results in seizure activity in aging Fischer 344 and Sprague Dawley rats
    Lutz et al.2004|Vertebrate brains at the pilot light
    Atlante et al.2017|A disease with a sweet tooth: exploring the Warburg effect in Alzheimer’s disease
    Sheth et al.2009|Antioxidant neuroprotection against ethanol-induced apoptosis in HN2-5 cells
    Gaur et al.2010|Protective effect of desipramine, venlafaxine and trazodone against experimental animal model of transient global ischemia: possible involvement of NO–cGMP pathway
    Shetty et al.2011|Age-induced alterations in hippocampal function and metabolism
    Labazi et al.2013|Metformin treatment improves erectile function in an angiotensin II model of erectile dysfunction
    Latchney et al.2015|Chronic P7C3 treatment restores hippocampal neurogenesis
    Annamalai et al.2015|Role of S-nitrosoglutathione mediated mechanisms in tau hyper-phosphorylation
    BE1027157B1|2020-10-26|Composition of sterol derivatives for its use in the treatment of neuronal pathology linked to hypoxia and / or hypoglycemia and corresponding composition
    Patel2012|Environmental enrichment: aging and memory
    Sedlic et al.2017|Non-linear actions of physiological agents: Finite disarrangements elicit fitness benefits
    Cary et al.2012|Melatonin: neuritogenesis and neuroprotective effects in crustacean x-organ cells
    FR2948026A1|2011-01-21|DIHYDRO-1,3,5-TRIAZINE AMINO DERIVATIVES FOR THE TREATMENT OF OXIDATIVE STRESS
    Scuderi et al.2019|Melatonin: implications for ocular disease and therapeutic potential
    de Carvalho Pereira et al.2017|Hypotensive effect and vascular relaxation in different arteries induced by the nitric oxide donor RuBPY
    Yiğit et al.2019|Effects of astaxanthin on antioxidant parameters in ARPE-19 cells on oxidative stress model
    Shuto et al.1998|Enhancement of serotonergic neural activity contributes to cyclosporine-induced tremors in mice
    Sharma et al.2011|ROLE OF Q–SWITCHED ND: YAG LASER IN NEVUS OF OTA: A STUDY OF 25 CASES
    Gupta et al.2014|Screening of antiangiogenic potential of twenty two marine invertebrate extracts of phylum Mollusca from South East Coast of India
    CA3148002A1|2021-02-04|Composition comprising sterol derivatives for use in the treatment of a neuronal pathology related to hypoxia, hypoglycemia and/or hyperglycemia
    同族专利:
    公开号 | 公开日
    BE1027157B9|2020-11-03|
    WO2021018798A1|2021-02-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2003089449A2|2002-04-19|2003-10-30|Institut National De La Sante Et De La Recherche Medicale|Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity|
    WO2016016518A2|2014-07-30|2016-02-04|Affichem|Use of sterol derivatives for treating neurosensory hearing loss, and corresponding composition|
    FR2981351A1|2011-10-17|2013-04-19|Univ Nice Sophia Antipolis|ANTI-DIABETIC AMINOSTEROIDIAN DERIVATIVES|
    法律状态:
    2020-12-04| FG| Patent granted|Effective date: 20201026 |
    优先权:
    申请号 | 申请日 | 专利标题
    BE20195501A|BE1027157B9|2019-08-01|2019-08-01|Composition of sterol derivatives for its use in the treatment of neuronal pathology linked to hypoxia and / or hypoglycemia and corresponding composition|BE20195501A| BE1027157B9|2019-08-01|2019-08-01|Composition of sterol derivatives for its use in the treatment of neuronal pathology linked to hypoxia and / or hypoglycemia and corresponding composition|
    PCT/EP2020/071044| WO2021018798A1|2019-08-01|2020-07-24|Composition comprising sterol derivatives for use in the treatment of a neuronal pathology related to hypoxia, hypoglycemia and/or hyperglycemia|
    [返回顶部]